The partner in your drug discovery, bridging the - Cellvax

Confidential
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: [phone]; Mobile: [phone]; Fax: 33 (0)
1 43 76 32 65. E-mail: <[e-mail]>; Web site: <www.cellvax-pharma.com>
1/20
Updated: Jan 2014
The partner in your drug discovery,
bridging the gap between R&D and
clinical applications
I. Major Activity
Cellvax SAS, French SME founded in 2001, is a service company (CRO) which
provides complete preclinical innovating services allowing accelerating the drug
development process for unmet needs related to severe human diseases, mainly
in Oncology and Osteoarthritis fields.
II. Mission
Cellvax’s main expertise: in vitro testing, original animal models in Oncology
and Osteoarthritis fields, both subcutaneous (S.C.) and orthotopic tumor models,
induced and spontaneous Osteoarthritis models, toxicity, bio-distribution,
PK/PD studies, in vivo imaging, histological analysis, etc., allowing speeding up
the development of your drug candidates and exploring their maximum potential
and mechanism of actions.

Confidential
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: [phone]; Mobile: [phone]; Fax: 33 (0)
1 43 76 32 65. E-mail: <[e-mail]>; Web site: <www.cellvax-pharma.com>
2/20
Cellvax’s competitive advantages: networking, Original animal models in
rodents & non-rodents (Mice, Rats, Hamsters, Guinea pigs, Rabbits, Cats, Dogs,
…); Numerous technical platforms, Reactivity, Confidentiality, Reliability,
Track records of our founder team, etc.
Cellvax positioning in drug discovery process:
Our services allow speeding up the development of your drug candidates,
valorizing drug potential and decreasing the cost of your drug development.
III. Cellvax presentation
Cellvax, founded in 2001, is a fast-growing technology-driven pre-clinical
service company focalizing on oncology and on Osteoarthritis. Today, Cellvax
directly employs and through R&D collaborations motivated and differently
skilled scientists and engineers, working in interdisciplinary teams on several
innovative products.
Since its foundation, Cellvax has significantly progressed as a service company,
especially in different cancer models in mice, angiogenesis models in vitro and
in vivo. Recently, we have developed several other models such as Oncology,
Osteoarthritis, Parkinson diseases, Diabetes, AMD, etc. in order to fully satisfy
Preclinical testsPreclinical tests
Candidate molecule
identification Pre-clinical trials Phase I Phase II Phase III Phase IV
Commercialization
Drug surveillance
Candidate molecule
identification Pre-clinical trials Phase I Phase II Phase III Phase IV
Commercialization
Drug surveillance
Clinical trailsClinical trails

Confidential
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: [phone]; Mobile: [phone]; Fax: 33 (0)
1 43 76 32 65. E-mail: <[e-mail]>; Web site: <www.cellvax-pharma.com>
3/20
the specific needs of our customers. We have concluded numerous contracts
with different companies in France, in Europe and in the world.
Here is a brief summary of Cellvax since its foundation in 2001:
Cellvax is always ready to adapt to the market evolution and to satisfy its
customers’ specific needs all over the world. Cellvax is strongly willing to
develop and enhance its national and international collaboration with public
laboratories, biotechnological companies and pharmaceutical companies in
cancer field. In this regard, Cellvax is also actively involved in different
European collaborative programs.
In 2007, Cellvax has successfully launched an EUREKA project in cancer field
named “Oligoclonics Σ!3942” entitled “An innovative technology and product
platform for improved antibody therapeutic” with another French partner (anti-
cancer center: Institut Gustave Roussy) and three partners from Holland. Under
this project, Cellvax has alrealy demonstrated its coordination and managerial
2001 2004 2006
3. Consolidation &
Expansion
EU FP-7
projects
20082007
French
Government
Grant, OSEO
1er EU
EUREKA
Foundation
New facility,
Multiple
animal species
2010
2. Strong
growth
1. Initiation
Early phases
clinical trials

Confidential
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: [phone]; Mobile: [phone]; Fax: 33 (0)
1 43 76 32 65. E-mail: <[e-mail]>; Web site: <www.cellvax-pharma.com>
4/20
skills within a European collaborative R&D environment and through its relation
with the Eureka Office and French funding body.
In 2011, Cellvax has successfully obtained a 2nd FP-7 grant “Piedpiper” for a
total amount of 2.4 millions €.
IV. Main Advantages
Cellvax’s project is founded by scientists and experts. Cellvax’s team is
composed of people who have a strong professional complementary which gives
a scientific, medical and industrial dimension of the company.
Our services are built on these advantages:
A. Present knowledge of Cellvax’s team
The new knowledge progress and the technological explosion in cellular and
molecular biology and genomics have helped tumors molecular detailed
analysis. Cellvax’s team totally controls these knowledges and the related

Confidential
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: [phone]; Mobile: [phone]; Fax: 33 (0)
1 43 76 32 65. E-mail: <[e-mail]>; Web site: <www.cellvax-pharma.com>
5/20
technologies in this field. Our services allow developing a therapeutic approach
which is more suitable for each patient and each biological target.
In order to expand our offers, Cellvax has recently moved to a new laboratory
facility, on the border of Paris, inside “Ecole Nationale Vétérinaire de Maisons
Alfort” (ENVA). The ENVA is one of the oldest and largest veterinary
universities in Europe, created in 1766 just on the border of Paris, with an easy
access by subway. In this new facility, Cellvax is able to provide a number of
new services especially with large animals (Mice, Rats, Hamsters, Guinea pigs,
Rabbits, Cats, Dogs, …), Numerous technical platforms, in vivo imaging plat-
forms, MRI, Scanner, Scintigraphy radio-labeled compounds, etc. In
consequence, Cellvax is able to provide the services not only in small animals,
but also in large animals in a more efficient way.
B. Our multidisciplinary expertise
Cellvax has a network of collaborations and is able to analyze tumoral and blood
biopsies in molecular biology. This network is composed of chemists, molecular
and cellular oncologists, immunologists, doctors, pharmacologists…